Cargando…
Drug–Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: Looking for Evidence Through a Systematic Review
BACKGROUND: Direct oral anticoagulants (DOACs), as substrates of cytochrome P450 (CYP) 3A4 and/or P-glycoprotein, are susceptible to drug–drug interactions (DDIs). Hepatitis C direct-acting antiviral agents (DAAs), via P-glycoprotein or CYP3A4 inhibition, may increase DOAC exposure with relevant ble...
Autores principales: | Bellesini, Marta, Bianchin, Matteo, Corradi, Chiara, Donadini, Marco Paolo, Raschi, Emanuel, Squizzato, Alessandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595962/ https://www.ncbi.nlm.nih.gov/pubmed/32809123 http://dx.doi.org/10.1007/s40261-020-00962-y |
Ejemplares similares
-
Risk–Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies
por: Raschi, Emanuel, et al.
Publicado: (2016) -
HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents
por: Angeletti, Andrea, et al.
Publicado: (2019) -
Drug–Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C
por: Gao, Lu-Hua, et al.
Publicado: (2021) -
Drug-drug interactions with direct-acting antivirals — less is more
por: Wong, Grace Lai-Hung
Publicado: (2021) -
HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
por: Rice, Donald P., et al.
Publicado: (2016)